Wire · opportunities
Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 September 2026 · Fusion42 review
MediLink's Tam-Peli demonstrated statistically significant improvement in overall survival and progression-free survival versus topotecan in a phase III trial for relapsed small-cell lung cancer in Chinese patients. Roche plans rapid global phase III trials and holds development and commercialisation rights outside China, Hong Kong, and Macau, with FDA and Chinese Breakthrough Therapy Designations already granted.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must act fast to position in relapsed small-cell lung cancer treatments in China as Tam-Peli sets a new survival benchmark with regulatory fast-tracking already underway. Roche’s push for global trials means international market expansion is imminent and competitive windows tighten.
◆ Coverage
1 source · 14 Sep 2026
◆ Related on Wire
◆ Topics